Key Takeaway
What is 5-Amino-1MQ? A research overview of the NNMT inhibitor peptide studied in metabolic and cellular energy pathways — mechanism, published research context, and how it relates to compounds available in Australia.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor that has attracted research interest in metabolic biology, cellular energy regulation, and adipose tissue modelling. Unlike most peptides in the research catalog space, 5-Amino-1MQ is not a peptide — it is a quinolinium compound studied for its effects on NAD+ metabolism and NNMT enzyme activity in preclinical models.
In research communities, 5-Amino-1MQ is sometimes grouped alongside metabolic research compounds because of its proposed role in modulating nicotinamide metabolism — a pathway that intersects with energy expenditure, mitochondrial function, and cellular redox balance. Understanding this distinction (small molecule vs peptide) is important when evaluating supplier catalogues and research protocols.
Mechanism of Action — NNMT Inhibition
NNMT is an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Elevated NNMT activity in adipose tissue has been associated with reduced NAD+ availability and altered metabolic signalling in published preclinical research.
5-Amino-1MQ acts as an NNMT inhibitor in cell culture and animal models, with research suggesting:
- Increased NAD+ availability in adipocytes and other cell types studied
- Reduced 1-MNA production via NNMT pathway blockade
- Effects on adipocyte size and lipid accumulation in rodent models
- Potential interaction with sirtuin and mitochondrial energy pathways downstream of NAD+ metabolism
These findings position 5-Amino-1MQ as a tool compound for studying NNMT-dependent metabolic regulation rather than as a direct analogue of incretin or GH-axis peptides.
Published Research Context
Research on 5-Amino-1MQ remains primarily preclinical. Key research themes in the literature include:
- Adipose tissue models: NNMT upregulation in obesity-associated adipose tissue and the effect of NNMT inhibition on adipocyte metabolism
- NAD+ metabolism: The relationship between NNMT activity, nicotinamide flux, and intracellular NAD+ pools
- Energy expenditure: Some rodent studies report changes in energy balance parameters following NNMT inhibition, though mechanisms and reproducibility vary across models
- Combination research: NNMT inhibition studied alongside other metabolic pathway modulators in multi-endpoint protocols
As with all research compounds outside established clinical pipelines, the preclinical dataset for 5-Amino-1MQ should be evaluated critically — effect sizes, model systems, and publication quality vary significantly.
5-Amino-1MQ vs Peptide Metabolic Research Compounds
Researchers comparing 5-Amino-1MQ to peptide metabolic compounds should note fundamental mechanistic differences:
- GLP-1 class peptides (Semaglutide, Tirzepatide, Retatrutide): incretin receptor agonists acting on appetite, glucose, and energy balance via gut-brain-pancreatic signalling. See EvoPeak guides for Retatrutide Australia and related GLP-1 research compounds.
- AOD-9604 / hGH fragments: lipolysis-focused peptides acting on adipose tissue via GH fragment pathways without full hGH receptor activation
- 5-Amino-1MQ: small-molecule NNMT inhibitor acting on nicotinamide metabolism — a distinct and non-overlapping mechanism from incretin or GH-axis peptides
For metabolic pathway research where NNMT inhibition is the specific research question, 5-Amino-1MQ is the relevant tool compound. For incretin or GH-axis research, peptide compounds with established receptor mechanisms are the appropriate starting materials.
Legal and Research-Only Context in Australia
In Australia, research chemicals sold for laboratory use with appropriate research-only disclaimers operate outside the TGA therapeutic goods framework when not marketed for human consumption or therapeutic use. This applies regardless of whether the compound is a peptide or a small molecule.
Researchers sourcing 5-Amino-1MQ or any research compound in Australia should apply the same quality criteria used for peptide sourcing:
- Batch-specific Certificate of Analysis with identity verification (HPLC and/or mass spectrometry as appropriate for the compound class)
- Third-party testing from an independent analytical laboratory
- Clear research-only positioning from the supplier — no therapeutic claims or human use instructions
- Local Australian fulfilment where possible to reduce transit time and customs risk
Related Metabolic Research Compounds at EvoPeak
EvoPeak supplies third-party tested metabolic research peptides for Australian researchers, including compounds commonly studied alongside or in comparison to NNMT pathway research:
- Retatrutide — triple GLP-1/GIP/Glucagon agonist for advanced metabolic pathway research
- Semaglutide — GLP-1 receptor agonist, extensive published research dataset
- Tirzepatide — dual GIP/GLP-1 receptor agonist
- AOD-9604 — hGH fragment for lipolysis research models
All EvoPeak products are sold strictly for laboratory research use. Browse the full metabolic research collection for available compounds with HPLC/MS verification and batch-specific COA documentation.
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule quinolinium compound, not a peptide. It is classified as an NNMT inhibitor and is structurally and mechanistically distinct from peptide research compounds.
What does 5-Amino-1MQ do in research models?
In published preclinical research, 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), which affects nicotinamide metabolism and NAD+ availability in studied cell types. Research has explored effects on adipocyte metabolism, energy balance parameters, and downstream NAD+-dependent signalling pathways in rodent models.
Can I buy 5-Amino-1MQ in Australia?
5-Amino-1MQ is not currently in the EvoPeak catalog. Australian researchers seeking metabolic research compounds can browse EvoPeak's metabolic collection for third-party tested peptides including Retatrutide, Semaglutide, Tirzepatide, and AOD-9604. This guide is provided for research education only.
How does 5-Amino-1MQ compare to Retatrutide?
They act on entirely different pathways. Retatrutide is a triple incretin receptor agonist peptide (GLP-1, GIP, glucagon) studied for metabolic effects via gut-brain-pancreatic signalling. 5-Amino-1MQ is a small-molecule NNMT inhibitor studied for effects on nicotinamide and NAD+ metabolism. They are not interchangeable research tools.
What quality documentation should I expect for research compounds in Australia?
Regardless of compound class, expect batch-specific COA documentation with identity verification (HPLC and/or MS as appropriate), purity analysis, and endotoxin screening where applicable. Third-party testing from an independent laboratory is preferred over in-house-only certification. See EvoPeak's COA reading guide for evaluation criteria.
Quality First
Verify purity before you research
EvoPeak provides batch-level HPLC/MS analysis, identity verification, and endotoxin screening for every compound.
Research & Educational Disclaimer: This article is for informational and educational purposes only. It references published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
